Online Trial Tracker - Larvol Sigma

Welcome, Profile Billing Logout

2 Trials

Active Trials Phase N/A

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Replagal (agalsidase alfa) / Samaritan Pharma, Takeda

NCT01031173: Treatment Protocol of Replagal for Patients With Fabry Disease

No Longer Available

N/A

agalsidase alfa, Replagal

Shire

Fabry Disease

NCT03230591: Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy

Recruiting

N/A

RoW

Echocardiography

Yonsei University

Fabry Disease

01/25

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites